This study aims to evaluate the safety and efficacy of RCZY690 therapy in participants with advanced malignant solid tumors. Participants will receive RCZY690 monotherapy until the end of the study.
Voluntarily participate in this study, sign the informed consent form, and be able to comply with the study protocol.
Age between 18 and 75 years inclusive.
ECOG performance status of 0 or 1.
Expected survival ≥ 12 weeks.
Female participants who are pregnant, lactating, or planning to become pregnant.
Participants with brain metastases.
History of severe bleeding tendency or coagulation dysfunction.
Toxicities from prior anti-tumor therapy have not recovered to Grade 1 per NCI-CTCAE version 6.0.
Parallel
RCZY690 Tablets
DrugOral medication. The patient will continue treatment until unacceptable toxic reactions occur, the disease progresses, or any criteria for leaving the study are met.
RCZY690 tables
DrugOral medication. The patient will continue treatment until unacceptable toxic reactions occur, the disease progresses, or any criteria for leaving the study are met.
Dose-Limiting Toxicity
Number of subjects with adverse events (AEs)
Maximum Tolerated Dose and/or Maximum Administered Dose
Recommended Phase 2 Dose
Objective Response Rate
Adverse Events/Serious Adverse Event
Disease Control Rate
Duration of Response
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
